siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice
Journal of Lipid Research · 2024
DOI: 10.1016/j.jlr.2024.100626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Yi Ding und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Taikang Center for Life and Medical Sciences, Taikang Medical School, Wuhan Unive…. Hauptthemen laut MEDLINE: Nanoparticles, Ubiquitin Thiolesterase, RNA, Small Interfering, Metabolic Syndrome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease is closely correlated with elevated low density lipoprotein-cholesterol. In feeding state, glucose and insulin activate mammalian target of rapamycin 1 that phosphorylates the deubiquitylase ubiquitin-specific peptidase 20 (USP20). USP20 then stabilizes HMG-CoA reductase, thereby increasing lipid biosynthesis. In this study, we applied clinically approved lipid nanoparticles to encapsulate the siRNA targeting Usp20. We demonstrated that silencing of hepatic Usp20 by siRNA decreased body weight, improved insulin sensitivity, and increased energy expenditure through elevating UCP1. In Ldlr-/- mice, silencing Usp20 by siRNA decreased lipid levels and prevented atherosclerosis. This study suggests that the RNAi-based therapy targeting hepatic Usp20 has a translational potential to treat metabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Taikang Center for Life and Medical Sciences, Taikang Medical School, Wuhan University, Wuhan, China.
- Department of Urology, Frontier Science Center for Immunology and Metabolism Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
- Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
- College of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Taikang Center for Life and Medical Sciences, Taikang Medical School, Wuhan University, Wuhan, China; Department of Urology, Frontier Science Center fo…
- College of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Taikang Center for Life and Medical Sciences, Taikang Medical School, Wuhan University, Wuhan, China. Electronic address: luxiaoyi@whu.edu.cn.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Ding, Y., Chen, Q. B., Xu, H., Adi, D., Ding, Y. W., Luo, W. J., Zhu, W. Z., Xu, J. C., Zhao, X., Shi, X. J., Luo, J., Yin, H., & Lu, X. Y. (2024). siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100626
Vancouver
Ding Y, Chen QB, Xu H, Adi D, Ding YW, Luo WJ, et al. siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100626
BibTeX
@article{Ding2024,
author = {Ding, Yi and Chen, Qiu-Bing and Xu, Hui and Adi, Dilare and Ding, Yi-Wen and Luo, Wen-Jun and Zhu, Wen-Zhuo and Xu, Jia-Chen and Zhao, Xiaolu and Shi, Xiong-Jie and Luo, Jie and Yin, Hao and Lu, Xiao-Yi},
title = {siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice},
journal = {Journal of Lipid Research},
year = {2024},
doi = {10.1016/j.jlr.2024.100626}
}
EUVIMED